zPREDICTA
zPREDICTA is developing organ-specific, physiologically-relevant 3D cell culture models providing a 1-to-1 reconstruction of human tissues. This is the only available 3D culture approach that comprehensively accounts for the major components of the cellular and extracellular tissue microenvironment preserving the critical interactions between a tumor and its surroundings. Clinical study data demonstrate the high correlation between drug efficacy measured in our platform and the clinical response
Y Combinator
yc-company-directory #1039zPREDICTA is developing organ-specific, physiologically-relevant 3D cell culture models providing a 1-to-1 reconstruction of human tissues. This is the only available 3D culture approach that comprehensively accounts for the major components of the cellular and extracellular tissue microenvironment preserving the critical interactions between a tumor and its surroundings. Clinical study data demonstrate the high correlation between drug efficacy measured in our platform and the clinical response
sourcezPREDICTA is classified as AI infrastructure from source descriptions and fund-directory context. Similar companies below are ranked from offline product facets and meaningful description overlap; category and source affiliation can only strengthen an existing product match. For lookup-created rows, the profile starts as pending enrichment until deeper source collection runs.
Local clusters rerank extracted product concepts and description terms. The generated graph remains the fallback for sparse descriptions: offline reciprocal product-similarity graph: extracted concepts + description terms + bounded category/affiliation boosts. Minimum fallback score: 0; max competitors: 6.
Companies similar to zPREDICTA
A deterministic local cluster built from offline product facets and meaningful description terms. Category and selected-institution affiliation provide bounded tie-breaks. Open any peer to continue exploring its cluster.
Known Medicine
match 95Known Medicine combines patient-specific 3D cell culture & AI to translate drugs to clinical success. We receive patient tumors, break them down, make thousands of micro-tumors, and then treat each with different drugs to determine which they will respond best to.
shared extracted concept terms: 3d, cell, culture; shared product terms: specific, 3d, cell, culture; shared product theme: health and clinical care; same category: AI infrastructure; shared affiliation: Y Combinator
Volumetric
match 64About Us Volumetric is a recognized world leader in building living multicellular tissues, with a focus on replicating discrete functions of the human body for basic mechanistic biology, laboratory testing and screening, and drug development. Founded in 2018 by Bagrat Grigoryan and Jordan Miller as a spin-out from Rice University, the full potential of our work is to build whole human organ replacements for patients, made from their own cells. Our Technology and Approach We have invented a suite
shared extracted concept terms: approach; shared product terms: tissue, human, drug, organ; shared product theme: health and clinical care; shared affiliation: Y Combinator
Eugit Therapeutics
match 57Eugit Therapeutics targets the issue of non-specific drugs that cause toxicity and clinical trial failures, affecting millions with tissue-specific inflammatory diseases. TAGHOME delivers drugs with precision to diseased tissues using T cell receptors, enhancing safety and improving efficacy. Our initial focus is on the 3.1 million U.S. individuals with Inflammatory Bowel Disease, aiming to initiate clinical trials within two years. Cofounded by George Church (Harvard) and funded by Y Combinator
shared product terms: specific, drug, clinical, tissue; shared product theme: health and clinical care; same category: AI infrastructure; shared affiliation: Y Combinator
Evolvere BioSciences
match 49🦠🤖 We use our computational models to make next-generation antibiotics that outcompete bacterial evolution and precisely target pathogenic bacteria, without harming good microbes or human cells. ☠️ Current antibiotics stop working because bacteria evolve resistance to them. This makes drug-resistant bacteria a looming global health crisis - already killing more people than malaria and AIDS and it is getting exponentially worse 📈. 🧬 Our approach leverages co-evolutionary protein-protein inter
shared product terms: model, human, cell, drug; shared product theme: health and clinical care; same category: AI infrastructure; shared affiliation: Y Combinator
Rejuvenation Technologies Inc.
match 46Stanford-patented essential drug platform unlocks the healthspan, which is limited by short telomeres. Extends mouse lifespan by equivalent of 10 years in humans. Reverses 5-10 years of telomere shortening with one dose in one day. Preclinical efficacy in 4 organ systems including immune system. Entering clinical stage. CEO is Subject #1 in longevity trial. 50+ granted patents, 7 patent families. FDA INTERACT cleared. Raising $10M seed extension ($2M+ wired) to fund 3 investigator-initiated tria
shared product terms: drug, human, efficacy, organ; shared product theme: health and clinical care; shared affiliation: Y Combinator
Acculis
match 39Using 3D models to help reduce errors in construction in the office and on-site
shared extracted concept terms: 3d, model; shared product terms: 3d, model; same category: AI infrastructure